OncoMatch/Clinical Trials/NCT06507514
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Is NCT06507514 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies blinatumomab and auto-HSCT "sandwich " strategy for b-cell acute lymphoblastic leukemia.
Treatment: blinatumomab and auto-HSCT "sandwich " strategy — Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main method potentially curing adult B-ALL, but the high treatment-related mortality (NRM) affects overall survival (OS). Autologous stem cell transplantation (auto-HSCT) can significantly reduce NRM but has a higher relapse rate. Studies have confirmed that achieving MRD negativity before Auto-HSCT can effectively reduce post-transplant relapse, achieving similar efficacy to allo-HSCT. The efficacy of blinatumomab in clearing MRD has been confirmed. Therefore, using blinatumomab combined with Auto-HSCT for B-ALL patients seems to make it possible to achieve benefits in leukemia free survival（LFS） and OS. The investigators first conducted blinatumomab and auto-HSCT "sandwich " strategy as consolidation therapy in patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive expression (positive)
positive expression of CD19 in peripheral blood or bone marrow primary cells detected by flow cytometry
Demographics
Prior therapy
Cannot have received: anti-cd19 therapy
Lab requirements
Kidney function
creatinine ≤ 1.6 mg/dl
Liver function
alt and ast ≤ 3 times the normal range and total bilirubin ≤ 2.0 mg/dl
Cardiac function
left ventricular ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06507514 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-cd19 therapy disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 15 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages